Log In
Print
BCIQ
Print
Print this Print this
 

ARN-810, GDC-0810, RG6046

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionOral selective estrogen receptor degrader (SERD)
Molecular Target Estrogen receptor
Mechanism of ActionEstrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat locally advanced or metastatic estrogen receptor-positive breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,725.0M

$725.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today